Context:

A novel daily pill, daraxonrasib, shown to block a common pancreatic cancer mutation, nearly doubles median survival in advanced cases that no longer respond to chemotherapy, raising hopes for a new standard of care. In a randomized trial of 500 patients with metastatic disease, those on the drug lived a median of 13.2 months versus 6.7 months on chemotherapy, with durable benefit and improved quality of life though not a cure. Researchers plan to pursue earlier use and potential surgical opportunities as tumor shrinkage may widen eligibility for procedures. The study, funded by Revolution Medicines, is advancing under accelerated FDA review and expanded access while scientists explore subtype-specific responses and broader applications. Side effects include rash and mouth sores, but overall tolerability was favorable compared with chemotherapy.

Dive Deeper:

• The therapy, daraxonrasib, targets KRAS mutations—key drivers in more than 90% of pancreatic cancer cases—and represents a novel approach after decades of limited targeted options.

• In the multicenter trial, participants with metastatic pancreatic cancer whose disease had progressed on prior treatments were randomly assigned to receive the pill or standard chemotherapy, with results published in the New England Journal of Medicine and presented at ASCO in Chicago.

• Daraxonrasib use was associated with a longer treatment duration and fewer severe adverse effects, contributing to improved patient-reported quality of life alongside tumor shrinkage.

• Experts described the finding as a potential turning point, with one commentator noting it could establish a new standard of care and prompting investigation of earlier-line use and potential resection opportunities for shrinking tumors.

• FDA plans to expedite review, and an expanded-access program is being offered to eligible patients while ongoing research seeks to identify which KRAS subtypes respond best and how to combine the drug with other therapies.

• Pancreatic cancer remains highly lethal, with about 67,000 new U.S. cases and 52,000 deaths expected this year, underscoring the significance of any meaningful extension of survival in this disease.

• The drug operates as a molecular glue to inhibit KRAS proteins, a long-elusive target, with researchers aiming to determine whether specific subtypes derive greater benefit and to explore complementary vaccines and therapies.